Enzymatic E-colicins bind to their target receptor BtuB by presentation of a small binding epitope on a coiled-coil scaffold

Arun K. Mohanty‡, Christopher M. Bishop§, Thomas C. Bishop¶, William C. Wimley§, and Michael C. Wiener‡‖

* This work was supported by National Institutes of Health Grant DK 59999 (to A.K.M. and M.C.W.) and National Institutes of Health Grant GM 60000 (to W.C.W.)

‡Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, 22908-0736, USA

§Department of Biochemistry, Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, USA

¶Environmental Health Sciences, Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, USA, and Division of Pharmaceutical Sciences, Xavier University of New Orleans, New Orleans, Louisiana, 70125, USA

‖To whom correspondence should be addressed: Dept. of Molecular Physiology and Biological Physics, University of Virginia, PO Box 800736, Charlottesville, VA 22908-0736. Tel.: 434-243-2731; E-mail: mwiener@virginia.edu

Running title: E-colicin binding to BtuB
Toxins and viruses often initiate their attacks by binding to specific proteins on the surfaces of target cells. Bacterial toxins (e.g. bacteriocins) and viruses (bacteriophages) targeting Gram-negative bacteria typically bind to outer-membrane proteins. Bacterial E-colicins target *Escherichia coli* by binding to the outer membrane cobalamin transporter BtuB. Colicins are tripartite molecules possessing receptor-binding, translocation and toxin domains connected by long coiled-coil α-helices. Surprisingly, the crystal structure of colicin E3 does not possess a recognizable globular fold in its receptor-binding domain. We hypothesized that the binding epitope of enzymatic E-colicins is a short loop connecting the two α-helices that comprise the coiled-coil region, and that this flanking coiled-coil region serves to present the loop in a binding-capable conformation. To test this hypothesis, we designed and synthesized a 34-residue peptide (‘E-peptide-1’) corresponding to residues A366-R399 of the helix-loop-helix region of colicin E3. Cysteines placed near the ends of the peptide (A372C and I393C) enabled crosslinking for reduction of conformational entropy and formation of a peptide structure that would present the loop epitope. A fluorescent analog was also made for fluorescence polarization binding. Our analysis shows that: 1) E-peptide-1 is predominantly random-coil in aqueous solution, but disulfide bond formation increases its α-helical content in both aqueous buffer and in solvents that promote helix formation; 2) Fluorescein-labeled E-peptide-1 binds to purified BtuB in a calcium-dependent manner with a $K_d$ of $43.6 \pm 4.9$ nM or $2370 \pm 670$ nM in the presence or absence of calcium, respectively; 3) In the presence of calcium, cyanocobalamin (CN-Cbl) displaces E-peptide-1 with a nanomolar inhibition constant $[K_i = 27.2 \pm 2.0$ nM]. We conclude that the BtuB binding sites for cobalamins and enzymatic E-colicins are
overlapping but inequivalent, and that the distal loop and (possibly) short α-helical flanking regions are sufficient for high-affinity binding.
E-colicin binding to BtuB

A critical first step for the action of many toxins and viruses is binding to proteins or other molecules at the external surface of the target cell. Examples of this process for eukaryotic targets include bacterial toxins and virulence factors that can bind to integrins or other eucaryotic receptors (1), as well as the human immunodeficiency virus that utilizes chemokine receptors (2) and the CD4 surface glycoprotein (3) as co-receptors. This process also occurs in the microbial world, with bacterial toxins (e.g. bacteriocins) and bacterial viruses (bacteriophages) binding to surface proteins of susceptible bacteria. Colicins are bacteriocins produced by and active against strains of *Escherichia coli* and closely related bacteria (4-7). Colicins bind to outer membrane proteins such as porins and transporters for cobalamins, siderophores, and nucleosides (4-7). E-colicins, a group of nine closely-related colicins ColE1-E9, bind to the *E. coli* outer membrane cobalamin transporter BtuB (8). The structure of BtuB (9) consists of a twenty-two stranded \( \beta \)-barrel with an amino-terminal hatch domain (Figure 1a). Cyanocobalamin (vitamin B\(_{12}\), CN-Cbl), a common substrate for BtuB, acts as an inhibitor for E-colicin binding and activity *in vivo* (10,11). The E-colicins lie in one of three cytotoxic classes: (i) membrane depolarizing (or pore forming) such as ColE1, (ii) DNase such as ColE2, E7, E8 and E9 and (iii) RNase such as ColE3, E4, E5 and E6 (7). The enzymatic colicins, Col E2-E9, are nearly identical in sequence except for the domains that encode their enzymatic activity.

The lethal action of colicins is executed by three consecutive stages that involve (a) binding to an outer-membrane receptor protein; (b) transport across the cell envelope; and (c) biochemical interaction with its target in the cell. These three steps are mediated by three separate parts of the protein: a receptor-binding (R) domain located in the central part of the primary sequence, an N-terminal translocation (T) domain, and a carboxy-terminal catalytic or channel forming (C) domain respectively. These domains are linked by long \( \alpha \)-helices that form
E-colicin binding to BtuB

a coiled-coil region. The first intact colicin structure, colicin Ia (12), illustrates clearly this tripartite architecture (Figure 1b). The first (and to date, only) intact E-colicin structure, colicin E3 (13), lacks a clearly identifiable globular R domain (Figure 1c). Where is the R domain in enzymatic E coli? The two long α-helices forming the coiled-coil region of ColE3 are linked by a short seven-residue ‘hairpin’ (A379-G385), and Soelaiman et al. (13) predicted that this loop binds to BtuB. Prior to the elucidation of the ColE3 structure, analysis of N- and C-terminal deletion constructs of ColE9 localized E-colicin R domain properties to a 76-residue region (Figure 1c); this polypeptide bound specifically to BtuB and inhibited the growth of a CN-Cbl-dependent strain of E. coli (14). Subsequent solution NMR studies of this construct, interpreted in the context of the ColE3 structure, indicate that it is a helical hairpin structure with multiple conformers in slow exchange and that the connecting loop is flexible (15). Other helix-loop-helix ColE3 domain constructs, of length 60-135 residues, have also been shown to bind specifically to BtuB (16,17). We hypothesized that the essential binding epitope of the enzymatic E-colicins is this short connecting loop, and that the coiled-coil region functions to present this loop in a conformation that is binding-competent. Therefore, much of this coiled-coil should be dispensable. We used structure-based design, then synthesized and characterized a 34-residue peptide of ColE3 (E-peptide-1, Figure 1d). E-peptide-1 binds with high affinity to purified BtuB, thus supporting the idea that the coiled-coil is primarily a scaffold for epitope presentation. The calcium-dependence of E-peptide-1 binding and its competitive displacement by the CN-Cbl suggest that enzymatic E-colicins and the cobalamin substrates of BtuB possess overlapping but inequivalent binding sites.
EXPERIMENTAL PROCEDURES

Peptide design – The design of E-peptide-1 started with the ColE3 wildtype sequence A366-R399. Since cyclization can significantly stabilize peptide tertiary structure (18,19) by decreasing conformational entropy, a disulfide linkage was engineered. Using SwissPDB viewer (20) with the ColE3 structure as a template, all possible Cys-Cys disulfides were modeled and energy minimized. Six possible disulfide-crosslinked peptides which had cysteine residues with normal Cα–Cβ-S and Cβ-S-S dihedral angles of 110° and 105°, respectively, and normal C-S and S-S distances of 1.55 Å and 1.90 Å, respectively, were identified. These variants all had backbone tertiary structures that were very similar to the native structure, with maximum atomic deviations of about 0.3 Å in the vicinity of the disulfide bond. From these six possibilities, F378C/W390C, I372C/A393C, D381C/H387C, A368C/A397C, F375C/W390C, and F375C/M389C, two (I372C/A393C and A368C/A397C) were nearly isovolumetric and did not alter the total charge of the sequence. From among these two, I372C/A393C was selected because it is closest to the native hydrophobicity (21) and because it is located in the middle of the coiled coil where the crosslink is expected to have the greatest stabilizing effect (Figure 1d).

Peptide synthesis and purification - E-peptide-1 was synthesized by FMOC chemistry (22,23) using an Applied Biosystems Pioneer Synthesizer. The solid support was PEG-PS-PAL resin (Applied Biosystems, Foster City, CA) with a loading of 0.25 mmol/gram. The groups pbf and Trt (22) were used for the critical sidechain protection of Arg and Cys, respectively. After observing large amounts of pbf adducts on Trp in a preliminary synthesis, Boc-protection of the Trp sidechain was used to prevent its recurrence. Protecting groups were cleaved efficiently using a 2-hour treatment with 90% trifluoroacetic acid, 5% thioanisole, 3% ethanedithiol and 2% anisole. Cleavage was performed in a dark N₂ atmosphere with the first 15 minutes of cleavage
carried out at 0°C and the remainder at room temperature. Cleaved peptide was filtered from the resin, dried immediately under a stream of nitrogen, and then lyophilized repeatedly from glacial acetic acid. Lyophilized E-peptide-1 was reduced with aqueous dithiothreitol and then partially purified with PolyCatA cation exchange resin (Western Analytical, Murietta, CA). Peptide was bound to the PolyCAT A resin, and then the dithiothreitol and other contaminants were removed by extensively washing the resin with water and isopropanol. Finally, the pure peptide was eluted from the resin with 45% acetic acid. Mass spectrometry on this material gave the mass of 3877 ± 2 Da (predicted mass, 3876.4 Da). There were no major contaminants, and no evidence that the acid-labile Asp-Pro bond (24) had been cleaved. Reduced E-peptide-1, which is highly soluble in water, was oxidized at 20 mg/ml for 24 hours in 10% DMSO/water (25). Oxidized peptide was analyzed with mass spectrometry and no evidence of crosslinked dimers or higher oligomers were found. We verified that the peptides were cyclized by cleaving the Asp-Pro bond at residue 16 in formic acid (24) and then using HPLC and mass spectrometry to show that the resulting single species was separated into two peptide species of the expected masses of 1838 and 2058 Da only upon disulfide bond reduction. Final purification of the cyclized E-peptide-1 peptide was done with C18 reverse phase HPLC. Linear E-peptide-1 was made by reduction with dithiothreitol and S-carboxyamidomethylation with iodoacetamide. Fluorescein-labeled E-peptide-1 was made by labeling the peptide’s amino-terminus with fluorescein succinimidyl ester (Molecular Probes, Eugene, OR) while the peptide was still attached to the solid support and while its lysine sidechains were still protected. Cleavage, deprotection, oxidation and purification of the labeled peptide were done as described above.

**CD spectroscopy** - Circular dichroism spectra of oxidized and reduced E-peptide-1 peptide were collected from samples in 0.1 mm path length quartz cuvette using a circular
E-colicin binding to BtuB

dichroism spectrometer (JASCO Model 810). Spectra were collected from 300 to 180 nm with 1
nm step size, 1 nm bandwidth, and at a rate of 10 nm/min. Spectra were recorded at 20-40 µM
peptide in distilled water or water that contained 30% or 60% trifluoroethanol, a helix promoting
solvent (26)

Fluorescence polarization binding assays - BtuB was expressed and purified as
previously described (27). The peak fractions after the final anion exchange purification step
were passed over PD-10 desalting columns (Amersham Biosciences, Piscataway, NJ) into assay
buffer (30mM Tris-Cl, pH 8.0, 0.6 % n-octyl tetraoxyethylene (C₈E₄; Anatrace Maumee, OH).
This assay buffer contains 1.5 µM free calcium as determined by fluorescence-ratio analysis of
Fluo-2 (Molecular Probes, Eugene, OR). BtuB concentration was determined by measurement of
A₂₈₀ and use an extinction coefficient of 198,329 M⁻¹ cm⁻¹ as determined by quantitative amino
acid analysis (W. M. Keck Facility, Yale University, New Haven, CT). E-peptide-1
concentration was determined in a similar way using an extinction coefficient ε₂₈₀ = 7,253 M⁻¹
cm⁻¹. Fluorescein-labeled E-peptide-1 concentration was measured by absorbance spectroscopy
using an extinction coefficient ε₄₉₈ = 88,000 M⁻¹ cm⁻¹ and used at a concentration of 5-6 nM in
the assays. The concentration of CN-Cbl was estimated by absorbance using A₃₆₁(1cm) = 204
(Merck Index, Twelfth edition). Fluorescence polarization (P) at 20°C was measured with a
Beacon 2000 Fluorescence Polarization Instrument (PanVera, Madison, WI) with filters at 490
nM (excitation) and 530 nM (emission). Fluorescence polarization (P) values were converted to
anisotropy (A) values by the equation A = 2P/(3–P); anisotropy of the free peptide was typically ~
0.1. Data were fitted, using KaleidaGraph (Synergy Software, Reading, PA), to the equation A =
A₁ + {(A₀–A₁)[protein]/(K₀+[protein]); A₁ and A₀ represent the anisotropy of the free and bound
peptides, respectively. Competitive binding studies were performed using BtuB and fluorescein-
labeled E-peptide-1 concentrations at which greater than 90% of the peptide was bound to BtuB. Competing ligands (CN-Cbl or unlabeled E-peptide-1) were added and the change in $P$ with ligand titration was measured. Anisotropy data were fitted to the equation $A = A_f + \{(A_b-A_f)[I]/(IC_{50}+[I])\}$, where $A_f$, $A_b$ and $I$ are anisotropy of free competing ligands, anisotropy of the bound competing ligands and total concentration of the competing ligands, respectively. The IC$_{50}$ value of each competing ligand was converted to $K_i$ by the equation $K_i = (0.5B)(IC_{50})(K_d)/[(L_T R_T)+0.5B(R_T-L_T+0.5B-K_d)]$, where $B$, $IC_{50}$, $L_T$ & $R_T$ are bound fluorescent ligand, concentration of competitor at 50% inhibition, total fluorescent ligand and total protein concentration respectively (29).

RESULTS

The $\alpha$-helical content of E-peptide-1 increases with disulfide bond formation – CD spectra are shown in Figure 2. Reduced, linear E-peptide-1 is random coil, with a broad minimum centered at 200 nM, and essentially zero ellipticity in the $\alpha$-helical region between 210 and 225 nm (30). Oxidized disulfide-linked E-peptide-1 has more ordered secondary structure in water as seen by: a shift in the minimum up to 204 nm, a crossover to a positive peak at 190 nm, and measurable ellipticity in the $\alpha$-helical region. Disulfide-linked E-peptide-1 contains about 10% helix in water, based upon the mean residue ellipticity at 222 nm. In the presence of 60% trifluoroethanol, a helix-promoting solvent, the helical content of disulfide-linked E-peptide-1 increases to ~40%, while reduced E-peptide-1 remains low at ~10%.

E-peptide-1 binds to BtuB with a calcium-dependent nanomolar affinity – Fluorescence polarization binding isotherms of fluorescein-labeled-E-peptide-1 are shown in Figure 3, and equilibrium binding constants $K_d$ are listed in Table 1. A single-site binding model adequately fits the observed data. In the presence of 100µM EGTA, fluorescein-labeled-E-peptide-1 binds
E-colicin binding to BtuB

with only micromolar affinity \[K_d = 2370 \pm 670 \text{ nM (n=4)}\]. Omission of EGTA and addition of 20 \(\mu\text{M CaCl}_2\) to the assay buffer dramatically increases binding affinity by greater than 50-fold \[K_d = 43.6 \pm 4.9 \text{ nM (n=4)}\]. The affinity decreases slightly, \(K_d = 73.9 \pm 8.3 \text{ nM (n=4)}\), in the standard assay buffer that contains 1.5 \(\mu\text{M free calcium}\).

Cyanocobalamin (CN-Cbl), a substrate for BtuB, displaces bound E-peptide-1 in the presence of calcium – The BtuB substrate CN-Cbl is able to displace competitively bound fluorescein-labeled E-peptide-1. Fluorescence polarization competitive binding isotherms are shown in Figure 4a, and equilibrium inhibition constants \(K_i\) are listed in Table 1. In the presence of 100\(\mu\text{M EGTA}\), CN-Cbl up to a maximum assay concentration of 66 \(\mu\text{M}\) is unable to displace bound fluorescein-labeled E-peptide-1. A single-site competitive binding model adequately fits the other observed data. Omission of EGTA and addition of 20 \(\mu\text{M CaCl}_2\) to the assay buffer enables CN-Cbl to now displace bound fluorescein-labeled E-peptide-1 with a nanomolar inhibition constant \([K_i = 27.2 \pm 2.0 \text{ nM (n=4)}]\). In the standard assay buffer that contains 1.5 \(\mu\text{M free calcium}\), \(K_i\) increases slightly to 31.7 \(\pm 3.6 \text{ nM (n=4)}\). The difference between these two values is not statistically significant. The ability of unlabeled E-peptide-1 to displace fluorescein-labeled E-peptide-1 was included as a positive control, and to determine the effect, if any, of the fluorescent moiety upon binding (Figure 4b). In contrast to competition by CN-Cbl, unlabeled E-peptide is able to displace bound fluorescein-labeled E-peptide-1 in the presence of 100\(\mu\text{M EGTA}\), although with a micromolar inhibition constant \([K_i = 1260 \pm 380 \text{ nM (n=2)}]\). Omission of EGTA and addition of 20 \(\mu\text{M CaCl}_2\) to the assay buffer dramatically increases inhibition by greater than 70-fold \([K_i = 17.2 \pm 7.4 \text{ nM (n=4)}]\). The inhibition constant increases slightly, \(K_d = 35.4 \pm 7.0 \text{ nM (n=3)}\), in the standard assay buffer.
DISCUSSION

We successfully used the crystal structure of ColE3 (13) as a template for design and construction of a minimal receptor-binding domain, E-peptide-1, that binds to the outer membrane cobalamin transporter BtuB with nanomolar affinity. This result supports the hypothesis that the primary binding epitope of enzymatic E-colicins is a short loop connecting the two α-helices that comprise the coiled-coil region, and (possibly) includes relatively short segments of this flanking coiled-coil region. In the colicin-binding event, the main function of the coiled-coil region is to form a scaffold for presentation of the loop epitope in a binding-competent conformation. Two peptide/protein design criteria were applied. First, minimize the length of the peptide while maintaining at least two to three turns of each of the α-helices flanking the putative loop epitope. Second, substitute two cysteines into the wildtype peptide sequence to enable formation of a disulfide crosslink for minimization of conformational entropy. Based on these criteria we selected the 34-residue peptide E-peptide-1 (corresponding to A366-R399, with cysteine substitutions A372C and I393C (Figure 1d). The E-peptide-1 sequence, in the context of the ColE3 crystal structure, is about 75% helical. In contrast, disulfide-linked E-peptide-1 is only about 10% helical in aqueous solvents. However, the helical content increases to approximately 40% in helix-promoting solvents. Critically, helical content of reduced and S-carboxyamidomethylated E-peptide-1, near zero in water, did not change in helix-promoting solvents. Although synthetic E-peptide-1 possesses less secondary structure than when its sequence is present within the entire ColE3 protein, the isolated peptide can form α-helical structure under the appropriate environmental conditions; these conditions may include an induced-fit mechanism upon binding to BtuB. Importantly, this structuring is significantly
E-colicin binding to BtuB

enhanced, i.e., $\Delta G_{\text{structure}}$ is more favorable, when the disulfide crosslink is in place.

Calcium is necessary for high-affinity binding of CN-Cbl to BtuB, with a 50-100-fold decrease in affinity when calcium is depleted (31). Crystal structures of BtuB show that the addition of calcium induces an ordering of extracellular loops of the $\beta$-barrel and indicate a direct structural role for these ions in high-affinity CN-Cbl binding. We observe an analogous calcium-dependent binding of E-peptide-1. Binding of fluorescein-labeled E-peptide-1 in the absence of calcium is greater than 54-fold weaker than in the presence of 20 $\mu$M calcium; competitive displacement of fluorescein-labeled E-peptide-1 by E-peptide-1 is more than 73-fold less effective (Table 1). The apparent $K_d$ of calcium binding to BtuB in isolated outer membranes is 30 nM (31); therefore, 20 $\mu$M calcium is saturating. In competition binding experiments, CN-Cbl displaces E-peptide-1 with a nanomolar inhibition constant in the presence of calcium, but cannot displace the peptide in calcium-depleted buffers. These two observations, a calcium dependence of E-peptide binding (like that of CN-Cbl binding) and displacement of E-peptide by Cn-Cbl, indicate that the binding sites of cobalamins and enzymatic E-colicins are similar. However, the inhibition constant [$K_i = 27.2 \pm 2.0$ nM ($n=4$)] for CN-Cbl to displace fluorescent-labeled E-peptide-1 from BtuB is 25 to a 100-fold larger than reported $K_d$ values for binding of CN-Cbl to BtuB (27,31). This result, that $K_d >> K_i$ for CN-Cbl interaction with BtuB, implies that the binding sites for cobalamins and enzymatic E-colicins overlap but are not equivalent.

Chemical modification experiments suggest that the ion-channel-forming E-colicin, ColE1, binds differently to BtuB than the enzymatic E-colicins ColE2 and ColE3 (32). This may reflect the different killing mechanisms of these two types of colicins. Following the binding event, enzymatic E-colicins are transported across both the outer and inner membranes in a process still rather poorly understood (33).
Acknowledgements – We thank Prof. Fraydoon Rastinejad for use of the fluorescence polarization instrument, and Mr. Li-Zhi Mi for technical advice regarding its operation.

REFERENCES


Table 1 Equilibrium binding constants of fluorescein-labeled-E-peptide-1, and competitive inhibitors CN-Cbl and E-peptide-1

<table>
<thead>
<tr>
<th>Buffer</th>
<th>$K_d$ (nM) (Fluorescein-labeled-E-peptide-1)</th>
<th>$K_i$ (nM) (CN-Cbl)</th>
<th>$K_i$ (nM) (E-peptide-1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard assay buffer (1.5 µM CaCl$_2$)</td>
<td>73.9 ± 8.3 (n = 4)</td>
<td>31.7 ± 3.6 (n = 4)</td>
<td>35.4 ± 7.0 (n = 3)</td>
</tr>
<tr>
<td>Standard assay buffer + 20 µM CaCl$_2$</td>
<td>43.6 ± 4.9 (n = 4)</td>
<td>27.2 ± 2.0 (n = 4)</td>
<td>17.2 ± 7.4 (n = 4)</td>
</tr>
<tr>
<td>Standard assay buffer + 100 µM EGTA</td>
<td>2370 ± 670 (n = 4)</td>
<td>No binding observed</td>
<td>1260 ± 380 (n = 2)</td>
</tr>
</tbody>
</table>
**FIGURE LEGENDS**

Figure 1 *Structures of BtuB and Colicins Ia and E3.*

(a) **(Left)** Apo-BtuB (1NQE, ref. 9) displaying hatch (magenta) and barrel (green) domains.

**(Right)** Ternary complex of BtuB (1NQH, ref. 9) displaying bound CN-Cbl (red) and calcium ions (yellow).

(b) **(Left)** Colicin Ia (1CII, ref. 12) illustrating the tripartite architecture of colicins.

Translocation (T), receptor-binding (R) and catalytic (C) domains are shown in green, red and magenta respectively. The coiled-coil region that connects these domains is shown in blue.

**(Right)** The Colicin E3 (1JCH, ref. 13) structure displaying T (green) and C (magenta) domains.

The immunity protein Im3 that is bound to ColE3 in the structure has been omitted for clarity.

Unlike colicin Ia, a globular receptor-binding domain is not apparent.

(c) The seventy-six residue sequence (343-418) of Colicin E9 that displayed BtuB-binding function (ref. 14) is mapped (in red) onto the ColE3 structure. These regions are at least 95% identical in all enzymatic E-colicins for which sequences are available.

(d) Sequence and design of E-peptide-1. **(Top)** Sequence E-peptide-1, corresponding to Ala366 to Arg399 in ColE3. In the synthetic peptide, Ala372 and Ile393 have been replaced with cysteines to make the indicated intramolecular disulfide crosslink. Residues that are in the helical coiled-coil in the native protein are underlined, and the residues in the extensive hydrophobic interface of the coiled-coils are highlighted in gray (N-terminal helix) and blue (C-terminal...
E-colicin binding to BtuB

helix). (Bottom Left) E-peptide-1 as mapped onto the ColE3 structure. A backbone trace in red indicates residues with helical conformation. Hydrophobic residues in the coiled-coil interface are shown in spacefilling mode using the same gray and blue color code as above in the sequence. (Bottom Right) The location of the disulfide linkage in the context of the native structure.

Figure 2 Circular dichroism spectra of cyclic, oxidized E-peptide-1 and linear, reduced E-peptide-1. Long dash-dot: Reduced peptide in water. Short Dash-dot: Reduced peptide in 60% TFE. Solid line: Oxidized peptide in water. Dashed line: Oxidized peptide in 30% TFE. Dotted line: Oxidized peptide in 60% TFE. The oxidized E-peptide-1 is more structured than the reduced peptide under all conditions.

Fig. 3 Binding isotherms of purified BtuB with fluorescein-labeled-E-peptide-1. Curves represent the best fit to the data as described in Experimental Procedures. Binding assays were performed in the standard assay buffer without added extra calcium (solid line with ●), in the buffer with 20 µM added CaCl₂ (broken lines with ■), in the buffer with 100 µM EGTA (dotted line with▲).

Fig. 4 Competition binding isotherms of CN-Cbl (a) and unlabeled E-peptide-1 (b) against fluorescein-labeled-E-peptide-1 bound to BtuB. Binding assays were performed in the buffer without added extra calcium (solid line with ●), in the buffer with 20 µM added CaCl₂ (broken lines with ■), in the buffer with 100 µM EGTA (dotted line with ▲).
Enzymatic E-coliins bind to their target receptor BtuB by presentation of a small binding epitope on a coiled-coil scaffold
Arun K. Mohanty, Christopher M. Bishop, Thomas C. Bishop, William C. Wimley and Michael C. Wiener

J. Biol. Chem. published online August 4, 2003